John Cockerell, MD
Family Medicine · North Little Rock, ARNPI 1669867099
Payments from drug & device makers
Across 600 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AbbVie$899
- Novo Nordisk$875
- AstraZeneca$815
- Lilly USA, LLC$717
- Amgen$657
- plus $4K from 34 others
What the payments were for
- Food & beverage$8,85199%
- Education$1311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 84 | $1,132 |
| AbbVie(2 entities) | 67 | $899 |
| Novo Nordisk | 57 | $875 |
| AstraZeneca | 27 | $815 |
| Lilly USA, LLC | 69 | $717 |
| Amgen | 42 | $657 |
| Abbott | 23 | $460 |
| Pfizer | 34 | $446 |
| Astellas Pharma US Inc | 20 | $428 |
| Merck | 23 | $300 |
| Boehringer Ingelheim | 17 | $286 |
| Antares Pharma, Inc. | 14 | $226 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $209 |
| Amarin Pharma, Inc. | 15 | $208 |
| Biohaven Pharmaceuticals, Inc. | 13 | $167 |
| Novartis | 9 | $131 |
| Corium, LLC | 6 | $122 |
| Phathom Pharmaceuticals, Inc. | 7 | $112 |
| Eisai Inc. | 8 | $104 |
| Teva Pharmaceuticals USA, Inc. | 8 | $99 |
| Supernus Pharmaceuticals, Inc. | 4 | $98 |
| Exact Sciences | 5 | $80 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| Sanofi Pasteur Inc. | 3 | $42 |
| Shire North American Group Inc | 3 | $38 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Dexcom, Inc. | 2 | $31 |
| Organon | 5 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Kaleo, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Tris Pharma Inc | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,982 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $98,645 |
| MounjaroTirzepatide | 74 | $87,364 |
| JardianceEmpagliflozin | 71 | $55,951 |
| EliquisApixaban | 60 | $44,497 |
| FarxigaDapagliflozin Propanediol | 49 | $42,790 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $40,684 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $18,951 |
| XareltoRivaroxaban | 19 | $17,286 |
| JanuviaSitagliptin Phosphate | 22 | $14,784 |
| MyrbetriqMirabegron | 17 | $8,741 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $8,709 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 236 | $7,133 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 12 | $6,874 |
| Duloxetine Hcl | 194 | $6,098 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $875 | $98,64590 claims |
| Lilly USA, LLCMounjaro | $717 | $87,36474 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $815 | $66,15195 claims |
| Boehringer IngelheimJardiance, Trijardy Xr | $286 | $62,82683 claims |
| PfizerEliquis, Premarin | $446 | $48,63071 claims |
| GSKTrelegy Ellipta | $1,132 | $40,68449 claims |
| Johnson & JohnsonXarelto | $16 | $17,28619 claims |
| MerckJanuvia | $300 | $14,78422 claims |
| Astellas Pharma US IncMyrbetriq | $428 | $8,74117 claims |
| Sanofi-aventis U.S. LLCLantus | $27 | $3,87620 claims |
| AbbVieSynthroid | $899 | $2,77538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in North Little Rock
- Michael BerryNorth Little Rock$18K
- Richard HeckNorth Little Rock$13K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.